The FLOW study continues to deliver groundbreaking insights into the benefits of GLP-1 receptor agonists for chronic kidney disease (CKD) in people with type 2 diabetes. In this episode, experts discuss the latest findings, revealing a 24% reduction in kidney disease progression, 18% reduction in major adverse cardiovascular events (MACE), and 20% reduction in total mortality - proving that this treatment saves hearts, kidneys, and lives.
Watch the full video on YouTube to learn how GLP-1 receptor agonists provide metabolic, cardiovascular, and renal benefits across different CKD stages, why early intervention is key, and how new research is uncovering the mechanisms behind these effects.